Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Borgmeier, Valeria"'
Autor:
Cai, Rui, Decuypere, Flore, Chevalier, Pierre, Desseilles, Martin, Lambert, Martin, Fakra, Eric, Wimmer, Antonie, Guillon, Pascal, Pype, Stefan, Godet, Annabelle, Borgmeier, Valeria
Publikováno v:
Cai, R, Decuypere, F, Chevalier, P, Desseilles, M, Lambert, M, Fakra, E, Wimmer, A, Guillon, P, Pype, S, Godet, A & Borgmeier, V 2022, ' Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium ', BMC Psychiatry, vol. 22, no. 1, 382 . https://doi.org/10.1186/s12888-022-03914-2
Background Long-acting antipsychotics (e.g. 1-monthly (PP1M) / 3-monthly (PP3M) injection forms of paliperidone palmitate) have been developed to improve treatment continuation in schizophrenia patients. We aim to assess risk factors of treatment dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::618316e6b605a254a3d0ab59aadcba7d
https://doi.org/10.1186/s12888-022-03914-2
https://doi.org/10.1186/s12888-022-03914-2
Autor:
Cai, Rui, Decuypere, Flore, Chevalier, Pierre, Desseilles, Martin, Lambert, Martin, Fakra, Eric, Wimmer, Antonie, Guillon, Pascal, Pype, Stefan, Godet, Annabelle, Borgmeier, Valeria
Additional file 1: FigureS1. Sensitivity analysis: treatmentdiscontinuation by product – patients newly initiated on paliperidone palmitateor risperidone microspheres (using a grace period of 120 days). FigureS2. Treatment discontinuation by produc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38cd7c1fbc07b271a31194baacf93a52
